Ascend does not dose ketamine in Lutz. Every session is given at 27724 Cashford Circle, Suite 102, Wesley Chapel, FL 33544, and no Lutz address should be read as a treatment location. There is no ketamine dosing suite in Lutz at Ascend, and the evaluation that decides whether ketamine suits your case can be done by Florida telehealth from home. The medication administered is a compounded preparation that is not FDA-approved, covered fully below. Call (813) 670-3005 or book a consultation.
Which symptoms tend to move first
Depression is not a single thing that improves or does not, and patients who expect a uniform lift are often the ones who conclude too early that nothing happened. The symptoms that respond first are usually the physical ones. Sleep consolidates. Appetite returns. The leaden heaviness in the limbs that makes ordinary tasks feel disproportionate tends to ease before mood itself shifts, and several patients describe the early change as being able to do things rather than wanting to.
Anhedonia, the loss of pleasure and interest, often moves next, and it is worth naming because it is the symptom people are least able to self-report accurately. It is easier to notice that a song landed, or that a conversation was not effortful, than to notice the absence of a flatness you had stopped registering. Rumination and self-critical thinking are typically slower, and hopelessness slower still. Anxiety can move in either direction early on, occasionally rising for a day or two before settling.
This is the reason symptom scores are recorded per visit and broken out rather than collapsed into one number. A patient whose sleep and energy have improved while mood has not is on a different trajectory than one where nothing has changed at all, and those two situations lead to different decisions about continuing. Tell the clinician what has moved, not only how the week felt overall, because the pattern is more informative than the summary.
Why this is scheduled care and not urgent care
Ketamine therapy is planned treatment assessed over weeks. The evaluation comes first, candidacy is decided on your history and a medical review, and the series is booked afterward. That sequence is not administrative caution. A monitored dose of a Schedule III controlled substance in a compounded preparation that is not FDA-approved is not something that should be arranged the same week someone calls in distress, and a practice that would do so is telling you something about how it makes decisions.
If you are in immediate danger, this is the wrong service and the right one is available now: call or text 988 for the Suicide and Crisis Lifeline, or go to your nearest emergency department. Neither of those is a lesser option than an appointment here. Acute risk needs a setting that can hold someone safely, which an outpatient dosing suite is not designed to do.
The ride requirement follows the same logic. You will not be cleared to drive after a session regardless of how alert you feel, and the arrangement is confirmed at check-in before any medication is given, because judgment and reaction time can remain affected after the obvious effects have faded. Plan the remainder of each session day as downtime, since most patients feel tired or foggy for several hours afterward.
The evaluation comes first, and it can say no
Nobody is dosed on the same visit as their first assessment. The psychiatric evaluation runs about an hour, is available by Florida telehealth or in person, and exists to answer two separate questions: whether ketamine is a defensible next step for your history, and whether anything makes it unsafe. The second can end the conversation regardless of the first. Either way you are told plainly that the medication under discussion is not FDA-approved before any decision is made.
Treatment-resistant depression is the primary and most studied indication, generally an inadequate response to two or more antidepressants at therapeutic doses for an adequate trial. PTSD is considered after trauma-focused therapy and first-line medication. Severe treatment-resistant anxiety, OCD, bipolar depression and select chronic pain conditions are each assessed individually and on thinner evidence. None are treated as certain to respond.
Screening covers severe or uncontrolled cardiovascular disease, uncontrolled hypertension, active psychosis or a documented primary psychotic disorder, active or untreated substance use disorders, and pregnancy, any of which can make this inappropriate. Bring a complete current medication list including supplements; benzodiazepines are the interaction discussed most often, with stimulants, several blood pressure medications and MAOIs also reviewed. If you are in immediate danger, call or text 988. This is scheduled care assessed over weeks, not an emergency service.
Subcutaneous dosing, monitored start to finish
A session takes about two hours. Roughly fifteen minutes of check-in and baseline vital signs, then a single small subcutaneous injection rather than a line kept in place for the duration, then forty to sixty minutes of active dose time in a recliner in a private treatment room with an eye mask and headphones available, then twenty to thirty minutes of recovery observation before discharge. Blood pressure, heart rate and your overall response are monitored throughout rather than checked once. The preparation given is compounded and not FDA-approved, which is precisely why that monitoring is fixed.
Most patients describe something dreamlike during the active window: detachment from the body, mild visual or perceptual changes, an altered sense of time, sometimes a floating sensation. That is anticipated rather than a complication, which is why nobody is left alone. Nausea, dizziness, brief rises in heart rate or blood pressure, and later headache or fatigue are the common transient effects and generally resolve before you leave.
Anna Stouffer, MS, PMHNP-BC, FNP-BC runs the evaluation, sets the dosing plan and reviews your response after every visit, with a trained clinical team member monitoring each session. She is dual board-certified in psychiatric-mental health and family practice, so the cardiovascular and medication review that determines candidacy happens in the same appointment. What treatment costs is discussed when we call you back rather than published, because it follows from what the evaluation concludes.
The FDA status of the compounded preparation
Ketamine is not FDA-approved to treat depression, PTSD, anxiety, OCD, or chronic pain. What Ascend administers is compounded, assembled by a pharmacy rather than manufactured and reviewed as a finished product, and a compounded medication is not FDA-approved for any use whatsoever. The agency has reviewed it for neither safety, nor effectiveness, nor manufacturing quality. You will hear this again during your evaluation and it is named explicitly in the informed consent you sign before a first dose, alongside the risks and the alternatives.
Because it is not FDA-approved, and because ketamine is a Schedule III controlled substance carrying genuine potential for misuse and dependence, two practices follow. Nothing is mailed and no supply is handed over for self-administration at home; the agency has warned publicly about compounded ketamine shipped for unsupervised use. And how often you dose is set by the clinic and reassessed at every follow-up rather than left running on an open-ended schedule. Ascend offers no nasal-spray and no at-home program.
There is one honest limit on the evidence. Most published research used infusion administration rather than the subcutaneous route given here, so what those trials found applies by reasonable inference rather than directly. We would rather name that than let anyone assume the studies tested precisely what they would receive. And whatever a trial reported, the compounded preparation used here is not FDA-approved.
Questions from Lutz patients
Does Ascend dose ketamine anywhere in Lutz?
Not one run by Ascend. There is no ketamine dosing suite in Lutz at Ascend. Every session happens at the Wesley Chapel suite, 27724 Cashford Circle, Suite 102. Lutz patients are evaluated through the practice, by telehealth or in person, and that evaluation decides whether a series is booked at all.
Do I need someone to drive me after every session?
Yes, every time, without exception. You will not be cleared to drive after a session and the team confirms your ride at check-in before anything is administered. This is not a formality that relaxes once you have done it a few times; it is confirmed at every visit, including a maintenance session months later, because judgment and reaction time can remain affected after the visible effects have faded.
Can I do the induction series without taking time off work?
Partly. Sessions run about two hours inside clinic hours and you cannot drive afterward, so a half day per session is the realistic unit, six times across two to three weeks. Say so at the evaluation if that is not workable, because the schedule can sometimes be spread differently. What is not adjustable is the monitoring: the observation period ends when you are cleared rather than at a fixed time, so a session occasionally runs longer than planned.
What if I need maintenance dosing later?
Maintenance is set by your response rather than a preset calendar. Some patients need none; others do well with a single session every four to eight weeks. The interval is decided from how long the effect actually holds for you rather than set in advance, and it is reviewed each time rather than left running indefinitely, because this is a controlled substance and the frequency is the practice's decision to make.
How is this different from an at-home ketamine service?
Supervision is what separates them. Home services send a compounded oral or sublingual preparation to take with no clinician present and no vital signs recorded. Ascend gives a monitored subcutaneous injection in a private room and does not mail medication. Neither is an FDA-approved product, so what you are actually choosing between is the level of supervision.
Does insurance cover this?
Rarely for the sessions. Coverage for racemic ketamine is inconsistent and usually out of network, and we do not bill insurance for the ketamine sessions themselves. The psychiatric consultation may be partially covered by in-network psychiatric benefits depending on your plan. See our insurance and payment page.
The nearest neighboring service-area page is Land O' Lakes. For how a dosing day is actually run, see the Wesley Chapel ketamine page; the service overview lives at ketamine therapy at Ascend.
References
- Zarate CA Jr, Singh JB, Carlson PJ, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Archives of General Psychiatry. 2006;63(8):856-864.
- Loo CK, Galvez V, O'Keefe E, et al. Placebo-controlled pilot trial testing dose titration and intravenous, intramuscular and subcutaneous routes for ketamine in depression. Acta Psychiatrica Scandinavica. 2016;134(1):48-56.
- Abdallah CG, Roache JD, Averill LA, et al. Dose-related effects of ketamine for antidepressant-resistant symptoms of posttraumatic stress disorder in veterans and active duty military: a double-blind, randomized, placebo-controlled multi-center clinical trial. Neuropsychopharmacology. 2022;47(8):1574-1581.